Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Phase 2 Terminated 96 enrolled Stem Cell Therapeutics Corp.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is: * To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control. * To assess the safety and tolerability of NTx®-265 when given to acute ischemic stroke patients.

Timeline

Start: 2009-08
Primary completion: 2010-04
Completion: 2010-04

Publications

Cramer SC, Hill MD; REGENESIS-LED Investigators. Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial). Int J Stroke. 2014 Apr;9(3):321-7. doi: 10.1111/ijs.12260. Epub 2014 Mar 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	epoetin alfa	Protein / enzyme biologic	4000 iu	Intravenous
Subject	epoetin alfa	Protein / enzyme biologic	12000 iu	Intravenous
Subject	epoetin alfa	Protein / enzyme biologic	20000 iu	Intravenous
Subject	human chorionic gonadotropin	Protein / enzyme biologic	385 ug	Subcutaneous

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Summary

Timeline

Publications

Drugs

Indications